TCGA-XF-A9SW-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 11.89224704
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- ANGIOGENESIS+0.550
- MYOGENESIS+0.530
- COAGULATION+0.430
- UV_RESPONSE_DN+0.420
- COMPLEMENT+0.350
- HEDGEHOG_SIGNALING+0.350
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.290
- APICAL_JUNCTION+0.270
Top 10 suppressed
- MYC_TARGETS_V2-0.630
- G2M_CHECKPOINT-0.510
- E2F_TARGETS-0.480
- MYC_TARGETS_V1-0.410
- MTORC1_SIGNALING-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.310
- DNA_REPAIR-0.300
- MITOTIC_SPINDLE-0.280
- P53_PATHWAY-0.200
- CHOLESTEROL_HOMEOSTASIS-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d3119bbd-8c3d-4f95-863c-a04ae8b18eb9 | — | — | 0.915 |
| 2 | TCGA-38-4627-01A-01R-1206-07 | — | cohortA1 | 0.915 |
| 3 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.909 |
| 4 | 4f709f4b-3140-47be-b55a-7713062545e9 | — | — | 0.896 |
| 5 | TCGA-CN-4728-01A-01R-1436-07 | — | — | 0.894 |
| 6 | TCGA-55-6980-01A-11R-1949-07 | — | cohortA1 | 0.889 |
| 7 | TCGA-GI-A2C8-01A-11R-A16F-07 | — | A | 0.888 |
| 8 | TCGA-XF-A9SL-01A-11R-A39I-07 | — | — | 0.888 |
| 9 | SRR12475153 | — | — | 0.887 |
| 10 | TCGA-E9-A1NF-01A-11R-A14D-07 | — | C | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.530 | Inavolisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.290 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.270 | Idelalisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.230 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.190 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |